BioSpace News Archive

The Progeria Research Foundation (PRF) today announced a historic milestone with the U.S. Food and Drug Administration (FDA) approval of Zokinvy™ (lonafarnib), for the treatment of Progeria and processing-deficient Progeroid Laminopathies (PL).

Fluidigm Corporation announced that the company’s management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, and Wednesday, December 2.

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020

Centene Corporation (NYSE: CNC) will host its 2021 Financial Guidance and Investor Meeting, in a virtual format, on Friday, December 18th, 2020.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or “the Company”), a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) – a rare disease for which there is no FDA-approved first-line therapy

AIkido Pharma Inc. (the “Company” or “AIkido”) (NASDAQ: AIKI) today announced the results from the virtual 2020 Annual Meeting of Stockholders (the “Meeting”) held on November 17, 2020 (the “Meeting”).

Testing represents the first crucial step towards identifying a medical problem and determining the optimal treatment regimen.

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease